Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1990 Oct;87(19):7375–7379. doi: 10.1073/pnas.87.19.7375

Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts.

K Tanaka 1, N L Tilney 1, K G Stunkel 1, W W Hancock 1, T Diamantstein 1, J W Kupiec-Weglinski 1
PMCID: PMC54749  PMID: 2217171

Abstract

A 10-day course with ART-18, a mouse monoclonal antibody (mAb) directed against the rat interleukin 2 receptor (IL-2R), prolongs the survival of (LEW x BN)F1 cardiac allografts in LEW recipients to approximately 3 weeks (acute rejection = 8 days, P less than 0.001). We examined host responses against ART-18 idiotype (Id) and mouse immunoglobulin in recipients immunomodulated with ART-18 mAb. Treatment with ART-18 elicited high titers of anti-Id antibodies 14 days after transplantation. However, naive rats given ART-18 before transplantation showed strong anti-Id responses as early as day 4 after engraftment, coinciding with abrogation of the treatment effect (graft survival, approximately 10 days). Preimmunization with irrelevant mouse IgG, which elicited high titers of anti-IgG, did not influence the efficacy of ART-18 upon graft survival (17 days). The use of cyclosporin A (CsA) in conjunction with ART-18 prior to transplantation suppressed the anti-Id response and led to dramatic graft prolongation (greater than 58 days), with two of five grafts surviving indefinitely. This striking effect of CsA plus ART-18 pretreatment did not depend upon CsA per se, as grafts were rejected within 12 days in animals pretreated with CsA alone; in both groups CsA trough levels were comparable. Moreover, administration of CsA before transplantation in concert with control IgG (instead of ART-18) prompted rejection within 2-4 weeks. Thus, discrete interaction(s) between anti-IL-2R mAb and CsA prior to engraftment induces partial host unresponsiveness/tolerance to anti-IL-2R mAb treatment following transplantation and suppresses the neutralizing anti-Id responses, which results in long-term/permanent graft acceptance. This study provides a strategy to overcome the anti-Id response mounted by graft recipients that otherwise limits the efficacy of anti-IL-2R mAb treatment.

Full text

PDF
7375

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cantarovich D., Le Mauff B., Hourmant M., Peyronnet P., Jacques Y., Boeffard F., Hirn M., Soulillou J. P. Prophylactic use of a monoclonal antibody (33B3.1) directed against interleukin 2 receptor following human renal transplantation. Am J Kidney Dis. 1988 Feb;11(2):101–106. doi: 10.1016/s0272-6386(88)80189-6. [DOI] [PubMed] [Google Scholar]
  2. Chatenoud L., Bach J. F. The therapeutic use of monoclonal antibodies. Curr Opin Immunol. 1988 Dec;1(2):257–260. doi: 10.1016/0952-7915(88)90011-8. [DOI] [PubMed] [Google Scholar]
  3. Chatenoud L., Baudrihaye M. F., Chkoff N., Kreis H., Goldstein G., Bach J. F. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol. 1986 Aug 1;137(3):830–838. [PubMed] [Google Scholar]
  4. Chatenoud L., Jonker M., Villemain F., Goldstein G., Bach J. F. The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science. 1986 Jun 13;232(4756):1406–1408. doi: 10.1126/science.3086976. [DOI] [PubMed] [Google Scholar]
  5. Cobbold S. P., Jayasuriya A., Nash A., Prospero T. D., Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984 Dec 6;312(5994):548–551. doi: 10.1038/312548a0. [DOI] [PubMed] [Google Scholar]
  6. Delmonico F. L., Fuller T. C., Russell P. S., Colvin R. B., Cosimi A. B. Variation in patient response associated with different preparations of murine monoclonal antibody therapy. Transplantation. 1989 Jan;47(1):92–95. doi: 10.1097/00007890-198901000-00021. [DOI] [PubMed] [Google Scholar]
  7. Goldstein G., Fuccello A. J., Norman D. J., Shield C. F., 3rd, Colvin R. B., Cosimi A. B. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation. 1986 Nov;42(5):507–511. doi: 10.1097/00007890-198611000-00013. [DOI] [PubMed] [Google Scholar]
  8. Granelli-Piperno A., Keane M., Steinman R. M. Evidence that cyclosporine inhibits cell-mediated immunity primarily at the level of the T lymphocyte rather than the accessory cell. Transplantation. 1988 Aug;46(2 Suppl):53S–60S. doi: 10.1097/00007890-198808001-00011. [DOI] [PubMed] [Google Scholar]
  9. Hannam-Harris A. C., Taylor D. S., Nowell P. C. Cyclosporin A directly inhibits human B-cell proliferation by more than a single mechanism. J Leukoc Biol. 1985 Aug;38(2):231–239. doi: 10.1002/jlb.38.2.231. [DOI] [PubMed] [Google Scholar]
  10. Hirsch R., Chatenoud L., Gress R. E., Sachs D. H., Bach J. F., Bluestone J. A. Suppression of the humoral response to anti-CD3 monoclonal antibody. Transplantation. 1989 May;47(5):853–857. doi: 10.1097/00007890-198905000-00021. [DOI] [PubMed] [Google Scholar]
  11. Hirsch R., Eckhaus M., Auchincloss H., Jr, Sachs D. H., Bluestone J. A. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol. 1988 Jun 1;140(11):3766–3772. [PubMed] [Google Scholar]
  12. Jonker M., Den Brok J. H. Idiotype switching of CD4-specific monoclonal antibodies can prolong the therapeutic effectiveness in spite of host anti-mouse IgG antibodies. Eur J Immunol. 1987 Nov;17(11):1547–1553. doi: 10.1002/eji.1830171104. [DOI] [PubMed] [Google Scholar]
  13. Kirkman R. L., Araujo J. L., Busch G. J., Carpenter C. B., Milford E. L., Reinherz E. L., Schlossman S. F., Strom T. B., Tilney N. L. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation. 1983 Dec;36(6):620–626. doi: 10.1097/00007890-198336060-00005. [DOI] [PubMed] [Google Scholar]
  14. Kirkman R. L., Shapiro M. E., Carpenter C. B., Milford E. L., Ramos E. L., Tilney N. L., Waldmann T. A., Zimmerman C. E., Strom T. B. Early experience with anti-Tac in clinical renal transplantation. Transplant Proc. 1989 Feb;21(1 Pt 2):1766–1768. [PubMed] [Google Scholar]
  15. Kreis H., Chkoff N., Vigeral P., Chatenoud L., Lacombe M., Campos H., Pruna A., Goldstein G., Bach J. F., Crosnier J. Therapeutic use of monoclonal antibodies in kidney transplantation. Adv Nephrol Necker Hosp. 1985;14:389–407. [PubMed] [Google Scholar]
  16. Kupiec-Weglinski J. W., Diamantstein T., Tilney N. L. Interleukin 2 receptor-targeted therapy--rationale and applications in organ transplantation. Transplantation. 1988 Dec;46(6):785–792. doi: 10.1097/00007890-198812000-00001. [DOI] [PubMed] [Google Scholar]
  17. Kupiec-Weglinski J. W., Diamantstein T., Tilney N. L., Strom T. B. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2624–2627. doi: 10.1073/pnas.83.8.2624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kupiec-Weglinski J. W., de Sousa M., Tilney N. L. The importance of lymphocyte migration patterns in experimental organ transplantation. Transplantation. 1985 Jul;40(1):1–6. doi: 10.1097/00007890-198507000-00001. [DOI] [PubMed] [Google Scholar]
  19. Müller C. E., Rajewsky K. Isolation of immunoglobulin class switch variants from hybridoma lines secreting anti-idiotope antibodies by sequential sublining. J Immunol. 1983 Aug;131(2):877–881. [PubMed] [Google Scholar]
  20. Niaudet P., Tete M. J., Broyer M., Habib R. Cyclosporine and childhood idiopathic nephrosis. Transplant Proc. 1988 Jun;20(3 Suppl 4):265–268. [PubMed] [Google Scholar]
  21. Osawa H., Diamantstein T. The characteristics of a monoclonal antibody that binds specifically to rat T lymphoblasts and inhibits IL 2 receptor functions. J Immunol. 1983 Jan;130(1):51–55. [PubMed] [Google Scholar]
  22. Pankewycz O. G., Hassarjian R., Chang C., Strom T. B., Kelley V. E. Anti-interleukin-2 receptor monoclonal antibody therapy induces anti-idiotypic antibodies in mice that block both in vitro and in vivo activity. J Autoimmun. 1988 Apr;1(2):119–130. doi: 10.1016/0896-8411(88)90020-0. [DOI] [PubMed] [Google Scholar]
  23. Perry L. L., Williams I. R. Regulation of transplantation immunity in vivo by monoclonal antibodies recognizing host class II restriction elements. I. Genetics and specificity of anti-Ia immunotherapy in murine skin allograft recipients. J Immunol. 1985 May;134(5):2935–2941. [PubMed] [Google Scholar]
  24. Ramos E. L., Milford E. L., Kirkman R. L., Tilney N. L., Strom T. B., Shapiro M. E., Waldmann T. A., Wood I. G., Rollins M. R., Carpenter C. B. Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody. Transplantation. 1989 Sep;48(3):415–420. doi: 10.1097/00007890-198909000-00012. [DOI] [PubMed] [Google Scholar]
  25. Reed M. H., Shapiro M. E., Strom T. B., Milford E. L., Carpenter C. B., Weinberg D. S., Reimann K. A., Letvin N. L., Waldmann T. A., Kirkman R. L. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation. 1989 Jan;47(1):55–59. doi: 10.1097/00007890-198901000-00013. [DOI] [PubMed] [Google Scholar]
  26. Shevach E. M. The effects of cyclosporin A on the immune system. Annu Rev Immunol. 1985;3:397–423. doi: 10.1146/annurev.iy.03.040185.002145. [DOI] [PubMed] [Google Scholar]
  27. Tanaka K., Hancock W. W., Osawa H., Stunkel K. G., Alberghini T. V., Diamantstein T., Tilney N. L., Kupiec-Weglinski J. W. Mechanism of action of anti-IL-2R monoclonal antibodies. ART-18 prolongs cardiac allograft survival in rats by elimination of IL-2R+ mononuclear cells. J Immunol. 1989 Nov 1;143(9):2873–2879. [PubMed] [Google Scholar]
  28. Tanaka K., Turka L. A., Ueda H., Diamantstein T., Milford E. L., Carpenter C. B., Tilney N. L., Kupiec-Weglinski J. W. Selective sparing of T suppressor cells by anti interleukin-2 receptor monoclonal antibodies (IL-2R mAbs) in vitro correlates with their therapeutic effects in vivo. Transplant Proc. 1989 Feb;21(1 Pt 1):475–476. [PubMed] [Google Scholar]
  29. Waldmann H. Monoclonal antibodies for organ transplantation: prospects for the future. Am J Kidney Dis. 1988 Feb;11(2):154–158. doi: 10.1016/s0272-6386(88)80203-8. [DOI] [PubMed] [Google Scholar]
  30. Zubler R. H., Lowenthal J. W., Erard F., Hashimoto N., Devos R., MacDonald H. R. Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. J Exp Med. 1984 Oct 1;160(4):1170–1183. doi: 10.1084/jem.160.4.1170. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES